Iovance Biotherapeutics, Inc
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers. Its current business centers on Amtagvi®, the first FDA-approved TIL therapy for advanced melanoma, and Proleukin®, an interleukin-2 product used in the Amtagvi regimen and other oncology settings.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved individualized cell therapy products sold for patient treatment, primarily Amtagvi®.
Proleukin® sales for approved oncology use, manufacturing support, and research applications.
Product sold to clinical manufacturers, research organizations, and trial settings.
Products
Reported · share of revenue- Amtagvi83.5 %
- Proleukin16.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Iovance sells primarily into the oncology care ecosystem: authorized treatment centers, specialty distributors, hospitals, and clinical/research users. Amtagvi demand is driven by patient referrals and treatment-center adoption, while Proleukin demand comes from both commercial oncology use and broader cell-therapy manufacturing and research needs.
Hospitals and cancer centers that procure and administer Amtagvi to eligible melanoma patients and drive therapy adoption.
Buy Proleukin in advance of expected infusions and oncology demand, especially in the U.S.
Purchase Proleukin for approved markets outside the U.S., supporting ex-U.S. oncology sales.
Use Proleukin in manufacturing processes, trials, and research settings for cell therapy workflows.
Strategy
Iovance is prioritizing the commercial launch of Amtagvi, expansion of the ATC network, and broader physician/patient awareness to increase referrals and infusion volume. It is also investing in centralized manufacturing scale, pipeline development, and cost reduction, including a 2025 restructuring intended to extend cash runway and focus resources on the highest-value programs.
The product is the company's first internally developed commercial therapy and the main growth engine.
Higher internal utilization should improve gross margin, control quality, and support larger patient volumes.
Additional indications and geographies are needed to broaden the addressable market beyond melanoma.
The company has a history of losses and needs to preserve liquidity while scaling the business.
Geography
Q1/2026The company is headquartered in the United States and derives most revenue from U.S. commercial launch activity, especially Amtagvi and Proleukin sales tied to that launch. It also sells Proleukin in international markets, with the reports specifically highlighting the EU and UK as important non-U.S. markets. Geography matters because U.S. demand is tied to ATC adoption and reimbursement, while ex-U.S. sales depend on local approvals and distributor channels.
Share of the revenue the company reports by geography.
Risks
Iovance remains exposed to execution risk because its revenue base is still early and concentrated in a small number of products, indications, and treatment centers. The company also faces typical biotech risks around clinical trial outcomes, regulatory approvals, manufacturing scale-up, reimbursement, and competition from better-capitalized oncology players.
- Clinical development riskImpact: HighLikelihood: High
Pipeline value depends on successful outcomes in registrational and confirmatory trials.
Exposure - Financing and liquidity riskImpact: HighLikelihood: High
The company has a history of operating losses and may need external capital if commercialization ramps slowly.
Exposure: Cash runway and future funding needs
- Commercial launch execution riskImpact: HighLikelihood: Medium
Amtagvi revenue depends on ATC adoption, referrals, and patient throughput, which are still developing.
Exposure: Amtagvi launch and ATC network
- Manufacturing and supply riskImpact: HighLikelihood: Medium
TIL therapies are individualized and operationally complex, so disruptions can affect patient treatment and margins.
Exposure - Competitive pressureImpact: MediumLikelihood: Medium
Larger biotech and pharma companies may develop alternative cancer therapies faster or with broader market acceptance.
Exposure: Melanoma and broader immuno-oncology markets
Accounting
Judgemental itemsAmtagvi is recognized upon infusion, while Proleukin is recognized on shipment/delivery, creating timing differences.
Impact: Quarterly revenue can shift with infusion timing and distributor stocking
Chargebacks, discounts, rebates, and sales allowances reduce reported product revenue.
Impact: Net sales can differ materially from gross billings
License agreements with Cellectis and Novartis may trigger future payments tied to development and sales.
Impact: Can increase operating expenses or cost of sales over time
The 2025 workforce reduction and operating restructuring require estimates for severance and related charges.
Impact: May create one-time charges and affect cash runway
Similar listed companies
Publicly listed companies with a comparable business focus.
Immunome Inc.
IMNM · Pharmaceutical Preparations
Immunocore Holdings plc
IMCR · Biological Products, (No Diagnostic Substances)
Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to…
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026